drugset / Trial / NCT01885000

Patient-Reported Outcome Of Facial Erythema (PROOF)

NCT01885000

Phase 3 Completed 92 enrolled Galderma R&D
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the study is to evaluate the patient-reported outcomes (feedbacks of patients)of a new drug for the treatment of erythema of rosacea (central facial redness). The feedback of patients receiving the active drug will be compared to the feedback of patients receiving the placebo.

Timeline

Start
2013-07-01
Primary completion
2013-11-14
Completion
2013-11-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Brimonidine Small molecule 0.5 % Topical

Indications